光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-057 光正眼科医院集团股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金井集团有限公司(KING JOIN GROUP LIMITED)(以下简称"金井集团")为 公司首次公开发行上市前股东，因该股东为外商投资企业，公司工商登记类型为 "股份有限公司（外商投资、上市）"。2025 年 7 月 9 日，公司收到股东金井 集团的《股东减持结果告知书》，其于 2025 年 6 月 10 日至 6 月 26 日期间通过 二级市场竞价交易的方式累计减持本公司股票 5,085,178 股，占公司总股本 0.98%。至此，该外资股东持有的公司股份全部减持完毕，公司的外商投资企业 性质已与实际情况不符。 公司于 2025 年 8 月 19 日召开第六届董事会第五次会议，审议通过了《关于 工商变更公司类型并修订《公司章程》的议案》,将公司类型由"股份有限公司 （外商投资、上市）"，变更为"股份有限公司（上市）"，具体以公司登记机 关核准的变更 ...

光正眼科医院集团股份有限公司 2025 半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：光正眼科医院集团股份有限公司 金额单位：人民币万元 | 非经营性资 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2025 年初 | 2025 半年度 | 2025 半年度 | 2025 半年度 | 2025 年 6 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 金占用 | | 司的关联关系 | 会计科目 | 占用资金 | 占用累计发 | 占用资金的 | 偿还累计发 | 月 30 日占 | 原因 | | | | | | | 余额 | 生金额（不含 | 利息（如有） | 生额 | 用资金余 | | | | | | | | | 利息） | | | 额 | | | | 现大股东及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | —— | —— | —— | - | - | - | - | - | —— | ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-059 光正眼科医院集团股份有限公司 除上述变更外，公司注册地址、公司网址等均保持不变，上述变更后的事项 自本公告披露之日起正式启用，敬请广大投资者关注，由此带来的不便，敬请谅 解。 特此公告。 关于变更办公地址及联系方式的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）因经营管理需要，公 司主要办公地址、投资者联系方式等发生变化，现就具体变更内容公告如下： | 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 办公地址 | 新疆维吾尔自治区乌鲁木齐经 | 上海市静安区中兴路 1618 | | | 济技术开发区融合北路 266 号 | 号 7-10 楼 | | 邮政编码 | 830012 | 200070 | | 投资者联系电话 | 0991-3766551 | 021-66290900 | | 电子邮箱 | luoping@xsjyk.com | investor@xsjyk.co ...

Group 1 - The core viewpoint of the article is that Guangzheng Eye Care has provided insights into its business segments, specifically the steel structure engineering and energy operation sectors [1] - The steel structure engineering segment is operated by Guangzheng Steel Structure Co., Ltd. and Guangzheng Construction Group Co., Ltd., focusing on the design, manufacturing, and construction of steel structures, and operates independently without involvement in the clean energy sector [1] - The energy operation segment includes subsidiaries such as Guangzheng Energy (Bazhou) Co., Ltd., Tuokexun County Xintianshan Gas Co., Ltd., and Xinjiang Tianyu Energy Technology Development Co., Ltd., primarily focusing on operation and asset leasing as its core business model [1] Group 2 - The company aims to continuously optimize its business layout and enhance operational efficiency to create long-term value for shareholders [1]

Group 1 - The core viewpoint of the article is that Guangzheng Eye Hospital clarified its operations in the steel structure engineering sector, emphasizing that it operates independently and does not engage in the clean energy field [1] Group 2 - The steel structure engineering segment is managed by Guangzheng Steel Structure Co., Ltd. and Guangzheng Construction Group Co., Ltd., focusing on the design, manufacturing, and construction of steel structures [1]

Market Performance - On August 13, the medical services sector rose by 4.02%, led by Innovative Medical [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Individual Stock Performance - The table lists various stocks in the medical services sector, with notable declines including *ST Bio down 4.95% and ST Zhongzhu down 2.66% [1] - Other stocks such as Lanwei Medical and Baicheng Pharmaceutical also experienced minor declines of 1.76% and 1.59% respectively [1] Capital Flow Analysis - The medical services sector saw a net inflow of 1.962 billion yuan from institutional investors, while retail investors experienced a net outflow of 1.888 billion yuan [3] - Notable stocks with significant net inflows from institutional investors include Yaoming Kande with 1.13 billion yuan and Kanglong Huacheng with 248 million yuan [3] - Conversely, retail investors showed significant outflows from stocks like Yaoming Kande and Kanglong Huacheng, indicating a shift in investor sentiment [3]

Summary of Key Points Core Viewpoint - On August 7, a total of 3 companies had their restricted shares unlocked, with a combined unlock volume of 19.2299 million shares, amounting to a market value of 1.202 billion yuan based on the latest closing price [1] Company-Specific Summaries - **Huahong Company**: - Unlock volume: 16.31 million shares - Unlock market value: 1.066 billion yuan - Unlock ratio of total share capital: 0.94% [1] - **Guangzheng Eye Hospital**: - Unlock volume: 1.9575 million shares - Unlock market value: 12.6 million yuan - Unlock ratio of total share capital: 0.38% [1] - **Anker Innovation**: - Unlock volume: 0.9624 million shares - Unlock market value: 9.1415 million yuan - Unlock ratio of total share capital: 0.18% [1]

Summary of Key Points Core Viewpoint - On August 7, a total of 3 companies had their restricted shares unlocked, with a combined unlock volume of 19.2299 million shares, amounting to a market value of 1.202 billion yuan based on the latest closing price [1] Company-Specific Summaries - **Hua Hong Company**: - Unlock volume: 16.31 million shares - Unlock market value: 1.066 billion yuan - Unlock ratio of total shares: 0.94% [1] - **Guangzheng Eye Hospital**: - Unlock volume: 1.9575 million shares - Unlock market value: 9.1415 million yuan - Unlock ratio of total shares: 0.38% [1] - **Anke Innovation**: - Unlock volume: 0.9624 million shares - Unlock market value: 12.6 million yuan - Unlock ratio of total shares: 0.18% [1]

Summary of Key Points Core Viewpoint The announcement details the first unlock period of the restricted stock incentive plan for Guangzheng Eye Hospital Group Co., Ltd., indicating that the conditions for unlocking have been met, allowing 1,957,500 shares to be released for trading, which represents 0.3776% of the company's total share capital [1][2][7]. Group 1: Incentive Plan Overview - The incentive plan involves a total of 221 participants, with the first unlock period allowing for the release of 1,957,500 shares [1][2]. - The plan's first unlock period is defined as starting from the completion of the grant registration and lasting until the last trading day within 24 months [7][10]. - The total number of restricted shares granted was adjusted from 919,994.6 thousand shares to 914,494.6 thousand shares due to the departure of three participants [6]. Group 2: Performance Conditions - The performance assessment for the unlock conditions is based on the company's revenue growth compared to the 2022 fiscal year, with specific targets set for each assessment year [9][10]. - The unlocking ratio is determined by the company's performance, with a maximum of 100% if the revenue growth meets or exceeds the target [10]. Group 3: Unlocking Details - Of the 221 eligible participants, 214 achieved a performance score of 80 or above, allowing for a full unlock, while 7 participants scored between 70 and 80, resulting in a partial unlock [11][12]. - The total number of shares eligible for unlocking is 1,957,500, with specific allocations detailed for individual participants [12][13]. Group 4: Share Structure Changes - Following the unlocking, the total number of unrestricted shares increased from 508,217,624 to 510,175,124, while restricted shares decreased from 10,249,450 to 8,291,950 [15]. - The overall share structure remains compliant with listing requirements, indicating no significant impact on the company's equity distribution [15].

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2025-051 光正眼科医院集团股份有限公司 关于 2023 年限制性股票激励计划首次部分授予的限制性股 票第一个解除限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.2023 年限制性股票激励计划首次部分授予的限制性股票第一个限售期符合解除限售 条件的激励对象共计 221 人，本次可解除限售股份数量总额为 1,957,500.00 股，占目前公 司股本总额的 0.3776%。 光正眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日分别召开了第六届董事会第四次会议和第六届监事会第四次会议，审议通过了 《关于 2023 年限制性股票激励计划首次部分授予的限制性股票第一个解除限售 期解除限售条件成就的议案》，根据《上市公司股权激励管理办法》、公司《2023 年限制性股票激励计划（草案）》等相关规定以及公司 2023 年度第三次临时股 东大会对董事会的授权，董事会认为公司 2023 年限制性股票激励计 ...